Kernal Biologics

Emerging

Company Overview

Kernal Biologics develops AI-programmed mRNA 2.0 therapeutics that enable scalable in vivo CAR-T therapies for cancer and autoimmune diseases. The Y Combinator-backed company has raised $35.8M in total funding, including a $25M Series A led by Hummingbird Ventures with participation from Amgen Ventures. Kernal's machine learning platform analyzes transcriptome data to design cell-specific therapeutic mRNAs, with its lead immuno-oncology candidate KR-335 advancing toward IND filing.

Revenue
$35.8M
Loading News...
Loading Timeline...
Loading Culture...
Loading Leadership...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Kernal Biologics is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

AI Visibility Rankings

How Kernal Biologics performs in AI search results

AI Rank
?
Track your position
Platforms
5
ChatGPT, Gemini, Claude...
Visibility
?
Your mention rate
Premium Feature

Unlock AI Visibility Tracking for Kernal Biologics

See exactly how Kernal Biologics ranks across ChatGPT, Gemini, Perplexity, Claude, and Grok. Get actionable insights to improve your AI search performance.

Real-time Rankings
Track your position daily
Competitive Intel
See how you compare
Platform Breakdown
Per-AI performance
Actionable Insights
Optimize your visibility
Start Tracking for Free

Join 1,000+ brands · Free 7-day trial · No credit card required

Want to improve your AI visibility? Track performance across all major AI platforms.
Compare with Other Brands

Compare with Other Brands

See how Kernal Biologics stacks up against competitors with our detailed comparison tool.

Start Comparison